1
|
Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol 2021; 5:1774-1778. [PMID: 31513236 DOI: 10.1001/jamaoncol.2019.2785] [Citation(s) in RCA: 357] [Impact Index Per Article: 119.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Importance Gut dysbiosis impairs response to immune checkpoint inhibitors (ICIs) and can be caused by broad-spectrum antibiotic (ATB) therapy. Objective To evaluate whether there is an association between ATB therapy administered concurrently (cATB) or prior (pATB) to ICI therapy and overall survival (OS) and treatment response to ICI therapy in patients with cancer treated with ICIs in routine clinical practice. Design, Setting, and Participants This prospective, multicenter, cohort study conducted at 2 tertiary academic referral centers recruited 196 patients with cancer who received ICI therapy between January 1, 2015, and April 1, 2018, in routine clinical practice rather than clinical trials. Main Outcomes and Measures Overall survival calculated from the time of ICI therapy commencement and radiologic response to ICI treatment defined using the Response Evaluation Criteria in Solid Tumors (version 1.1), with disease refractory to ICI therapy defined as progressive disease 6 to 8 weeks after the first ICI dose without evidence of pseudoprogression. Results Among 196 patients (137 men and 59 women; median [range] age, 68 [27-93] years) with non-small cell lung cancer (n = 119), melanoma (n = 38), and other tumor types (n = 39), pATB therapy (HR, 7.4; 95% CI, 4.3-12.8; P < .001), but not cATB therapy (HR, 0.9; 95% CI, 0.5-1.4; P = .76), was associated with worse OS (2 vs 26 months for pATB therapy vs no pATB therapy, respectively) (hazard ratio [HR], 7.4; 95% CI, 4.2-12.9) and a higher likelihood of primary disease refractory to ICI therapy (21 of 26 [81%] vs 66 of 151 [44%], P < .001). Overall survival in patients with non-small cell lung cancer (2.5 vs 26 months, P < .001), melanoma (3.9 vs 14 months, P < .001), and other tumor types (1.1 vs 11, P < .001) was consistently worse in those who received pATBs vs those who did not. Multivariate analyses confirmed that pATB therapy (HR, 3.4; 95% CI, 1.9-6.1; P < .001) and response to ICI therapy (HR, 8.2; 95% CI, 4.0-16.9; P < .001) were associated with OS independent of tumor site, disease burden, and performance status. Conclusions and Relevance Despite being limited by sample size, geographic origin, and the lack of correlative analyses on patients' gut microbiota, this study suggests that pATB therapy but not cATB therapy is associated with a worse treatment response and OS in unselected patients treated with ICIs in routine clinical practice. Mechanistic studies are urgently required to investigate ATB-mediated alterations of gut microbiota as a determinant of poorer outcome following ICI treatment.
Collapse
Affiliation(s)
- David J Pinato
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.,Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Sarah Howlett
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Diego Ottaviani
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Heather Urus
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Aisha Patel
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Takashi Mineo
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.,Tokyo Medical and Dental University, Tokyo, Japan
| | - Cathryn Brock
- Department of Oncology, Chelsea and Westminster Hospital, London, United Kingdom
| | - Danielle Power
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Olivia Hatcher
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Alison Falconer
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Manasi Ingle
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Anna Brown
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Dorothy Gujral
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Sarah Partridge
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Naveed Sarwar
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Michael Gonzalez
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Maggie Bendle
- Department of Oncology, Chelsea and Westminster Hospital, London, United Kingdom
| | - Conrad Lewanski
- Department of Oncology, Imperial College NHS Trust, Charing Cross Hospital, London, United Kingdom
| | - Thomas Newsom-Davis
- Department of Oncology, Chelsea and Westminster Hospital, London, United Kingdom
| | - Elias Allara
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.,Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Mark Bower
- Department of Oncology, Chelsea and Westminster Hospital, London, United Kingdom
| |
Collapse
|
2
|
Dubash S, Inglese M, Mauri F, Kozlowski K, Trivedi P, Arshad M, Challapalli A, Barwick T, Al-Nahhas A, Stanbridge R, Lewanski C, Berry M, Bowen F, Aboagye EO. Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [ 18F]fluoromethyl-(1,2- 2H 4)-choline. Theranostics 2020; 10:8677-8690. [PMID: 32754271 PMCID: PMC7392021 DOI: 10.7150/thno.47298] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Accepted: 06/19/2020] [Indexed: 12/26/2022] Open
Abstract
Purpose: The spatio-molecular distribution of choline and its metabolites in tumors is highly heterogeneous. Due to regulation of choline metabolism by hypoxic transcriptional signaling and other survival factors, we envisage that detection of such heterogeneity in patient tumors could provide the basis for advanced localized therapy. However, non-invasive methods to assess this phenomenon in patients are limited. We investigated such heterogeneity in Non-Small Cell Lung Cancer (NSCLC) with [18F]fluoromethyl-(1,2-2H4) choline ([18F]D4-FCH) and positron emission tomography/computed tomography (PET/CT). Experimental design: [18F]D4-FCH (300.5±72.9MBq [147.60-363.6MBq]) was administered intravenously to 17 newly diagnosed NSCLC patients. PET/CT scans were acquired concurrently with radioactive blood sampling to permit mathematical modelling of blood-tissue transcellular rate constants. Comparisons were made with biopsy-derived choline kinase-α (CHKα) expression and diagnostic [18F]fluorodeoxyglucose ([18F]FDG) scans. Results: Oxidation of [18F]D4-FCH to [18F]D4-fluorobetaine was suppressed (48.58±0.31% parent at 60 min) likely due to the deuterium isotope effect embodied within the design of the radiotracer. Early (5 min) and late (60 min) images showed specific uptake of tracer in all 51 lesions (tumors, lymph nodes and metastases) from 17 patients analyzed. [18F]D4-FCH-derived uptake (SUV60max) in index primary lesions (n=17) ranged between 2.87-10.13; lower than that of [18F]FDG PET [6.89-22.64]. Mathematical modelling demonstrated net irreversible uptake of [18F]D4-FCH at steady-state, and parametric mapping of the entire tumor showed large intratumorally heterogeneity in radiotracer retention, which is likely to have influenced correlations with biopsy-derived CHKα expression. Conclusions: [18F]D4-FCH is detectable in NSCLC with large intratumorally heterogeneity, which could be exploited in the future for targeting localized therapy.
Collapse
Affiliation(s)
- Suraiya Dubash
- Department of Surgery and Cancer, Imperial College London, United Kingdom
| | - Marianna Inglese
- Department of Surgery and Cancer, Imperial College London, United Kingdom
| | - Francesco Mauri
- Department of Surgery and Cancer, Imperial College London, United Kingdom
| | - Kasia Kozlowski
- Department of Surgery and Cancer, Imperial College London, United Kingdom
| | - Pritesh Trivedi
- Department of Surgery and Cancer, Imperial College London, United Kingdom
| | - Mubarik Arshad
- Department of Surgery and Cancer, Imperial College London, United Kingdom
- Department of Radiology/Nuclear Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom
| | | | - Tara Barwick
- Department of Surgery and Cancer, Imperial College London, United Kingdom
- Department of Radiology/Nuclear Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Adil Al-Nahhas
- Department of Radiology/Nuclear Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Rex Stanbridge
- Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Conrad Lewanski
- Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Matthew Berry
- Department of Medicine and Integrated Care, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Frances Bowen
- Department of Medicine and Integrated Care, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Eric O. Aboagye
- Department of Surgery and Cancer, Imperial College London, United Kingdom
| |
Collapse
|
3
|
Ponce Aix S, Talbot D, Govindan R, Dols MC, Postmus PE, Lewanski C, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Ong TJ, Morgensztern D. Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. Future Oncol 2020; 16:749-762. [PMID: 32228198 DOI: 10.2217/fon-2019-0796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.
Collapse
Affiliation(s)
- Santiago Ponce Aix
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Denis Talbot
- Department of Medical Oncology, Oxford University Hospitals NHS Foundation Trust, Oxfordshire, UK
| | - Ramaswamy Govindan
- Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
| | - Manuel Cobo Dols
- Department of Medical Oncology, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain
| | - Pieter E Postmus
- Department of Medical Oncology, The Clatterbridge Cancer Centre, Liverpool, UK
| | - Conrad Lewanski
- Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - Jaafar Bennouna
- Department of Medical Oncology, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Nantes, Loire-Atlantique, France
| | - Juergen R Fischer
- Department of Medical Oncology, Lungenklinik Löwenstein gGmbH, Löwenstein, Baden-Württemberg, Germany
| | - Oscar Juan-Vidal
- Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - David J Stewart
- Department of Medical Oncology, Ottawa Hospital, Ottawa, ON, Canada
| | - Andrea Ardizzoni
- Department of Medical Oncology, Azienda Ospedaliero Universitaria Di Bologna, Policlinico S Orsola-Malpighi, Bologna, Italy
| | | | | | - Martin Reck
- LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
| | | | - Daniel Morgensztern
- Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
| |
Collapse
|
4
|
Dubash SR, Merchant S, Heinzmann K, Mauri F, Lavdas I, Inglese M, Kozlowski K, Rama N, Masrour N, Steel JF, Thornton A, Lim AK, Lewanski C, Cleator S, Coombes RC, Kenny L, Aboagye EO. Clinical translation of [ 18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. Eur J Nucl Med Mol Imaging 2018; 45:2285-2299. [PMID: 30259091 PMCID: PMC6208806 DOI: 10.1007/s00259-018-4098-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Accepted: 07/17/2018] [Indexed: 01/17/2023]
Abstract
BACKGROUND Effective anticancer therapy is thought to involve induction of tumour cell death through apoptosis and/or necrosis. [18F]ICMT-11, an isatin sulfonamide caspase-3/7-specific radiotracer, has been developed for PET imaging and shown to have favourable dosimetry, safety, and biodistribution. We report the translation of [18F]ICMT-11 PET to measure chemotherapy-induced caspase-3/7 activation in breast and lung cancer patients receiving first-line therapy. RESULTS Breast tumour SUVmax of [18F]ICMT-11 was low at baseline and unchanged following therapy. Measurement of M30/M60 cytokeratin-18 cleavage products showed that therapy was predominantly not apoptosis in nature. While increases in caspase-3 staining on breast histology were seen, post-treatment caspase-3 positivity values were only approximately 1%; this low level of caspase-3 could have limited sensitive detection by [18F]ICMT-11-PET. Fourteen out of 15 breast cancer patients responded to first-line chemotherapy (complete or partial response); one patient had stable disease. Four patients showed increases in regions of high tumour [18F]ICMT-11 intensity on voxel-wise analysis of tumour data (classed as PADS); response was not exclusive to patients with this phenotype. In patients with lung cancer, multi-parametric [18F]ICMT-11 PET and MRI (diffusion-weighted- and dynamic contrast enhanced-MRI) showed that PET changes were concordant with cell death in the absence of significant perfusion changes. CONCLUSION This study highlights the potential use of [18F]ICMT-11 PET as a promising candidate for non-invasive imaging of caspase3/7 activation, and the difficulties encountered in assessing early-treatment responses. We summarize that tumour response could occur in the absence of predominant chemotherapy-induced caspase-3/7 activation measured non-invasively across entire tumour lesions in patients with breast and lung cancer.
Collapse
Affiliation(s)
- S R Dubash
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - S Merchant
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - K Heinzmann
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - F Mauri
- Department of Radiology, Imperial College Healthcare NHS Trust, London, UK
| | - I Lavdas
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - M Inglese
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
- Department of Computer, Control and Management Engineering Antonio Ruberti, University of Rome, La Sapienza, Italy
| | - K Kozlowski
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - N Rama
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - N Masrour
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - J F Steel
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - A Thornton
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK
| | - A K Lim
- Department of Radiology, Imperial College Healthcare NHS Trust, London, UK
| | - C Lewanski
- Department of Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - S Cleator
- Department of Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - R C Coombes
- Department of Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - Laura Kenny
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK.
- Department of Oncology, Imperial College Healthcare NHS Trust, London, UK.
| | - Eric O Aboagye
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Rd, London, W120NN, UK.
| |
Collapse
|
5
|
Popat S, Januszewski A, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Howarth K, Cinelli M, Green E, Morris C, Ngai Y, Hackshaw A. P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Morgensztern D, Govindan R, Cobo M, Ponce Aix S, Postmus P, Lewanski C, Bennouna J, Fischer J, Juan-Vidal O, Stewart D, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Ong T. P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Talbot D, Govindan R, Cobo M, Ponce Aix S, Postmus P, Lewanski C, Bennouna J, Fischer J, Juan-Vidal O, Stewart D, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Morgensztern D, Ong T. P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE. Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncol 2018; 14:2415-2431. [PMID: 29978725 DOI: 10.2217/fon-2018-0330] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit. Recommendations on the use of immune checkpoint inhibitor in clinically challenging populations are also provided.
Collapse
Affiliation(s)
- Raffaele Califano
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
- Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, UK
- Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - Rohit Lal
- Lung Cancer Unit, Guy's & St Thomas' Hospital, London, UK
| | | | | | - Christian H Ottensmeier
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton & University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Sanjay Popat
- Royal Marsden Hospital & the National Heart & Lung Institute, Imperial College London, London, UK
| | | | - Pieter E Postmus
- Clatterbridge Cancer Centre, Liverpool Heart & Chest Hospital, University of Liverpool, Liverpool, UK
| |
Collapse
|
9
|
Mazières J, Park K, Lewanski C, Gadgeel S, Fehrenbacher L, Rittmeyer A, Han JY, Artal-Cortes A, Braiteh F, Vansteenkiste J. 136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR). J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30410-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
10
|
Elshiekh M, Mani A, Kitson R, Josephides E, Clifford A, Desai S, Gupta N, Bowen F, Berry M, Bloch S, Ross C, Counihan I, Anderson J, Nandi J, Roddie M, Copley S, Hatcher O, Denton A, Power D, Lewanski C, Newsom-Davis T, Viola P. Non-small cell lung cancers (NSCLC) and programmed death ligand 1 (PD-L1) testing: multicentric analysis of clinical, pathological and molecular features. Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30151-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget 2017; 7:13209-20. [PMID: 26334099 PMCID: PMC4914352 DOI: 10.18632/oncotarget.4801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2015] [Accepted: 08/11/2015] [Indexed: 11/25/2022] Open
Abstract
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT preferentially improves EFS in comparison to NC followed by adjuvant trastuzumab initiated postoperatively (NCAT) has not been addressed. Using clinical data from women with HER2 positive BC treated at 7 European institutions between 2007 and 2010 we sought to investigate the impact on breast cancer outcomes of concomitant (NCT) versus sequential (NCAT) treatment in HER2 positive early BC. The unadjusted hazard ratio (HR) for event free survival with NCT compared with NCAT was 0.63 (95% CI 0.37-1.08; p = 0.091). Multivariable analysis revealed that treatment group, tumour size and ER status were significantly associated with EFS from diagnosis. In the whole group NCT was associated with a reduced risk of an event relative to NCAT, an effect that was confined to ER negative (HR: 0.25; 95% CI, 0.10-0.62; p = 0.003) as opposed to ER positive tumours (HR: 1.07; 95% CI, 0.46-2.52; p = 0.869). HER2 positive/ER negative BC treated with NC gain greatest survival benefit when trastuzumab is administered in both the neoadjuvant and adjuvant period rather than in the adjuvant period alone. These data support the early introduction of targeted combination therapy in HER2 positive/ER negative BC.
Collapse
Affiliation(s)
- Carlo Palmieri
- Academic Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.,Liverpool and Merseyside Academic Breast Unit, The Linda McCartney Centre, Royal Liverpool University Hospital, Liverpool, UK.,The University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, UK
| | - Iain Rj Macpherson
- Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Kelvin Yan
- Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - Felipe Ades
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Pippa Riddle
- Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.,Department of Clinical Oncology, West Middlesex University Hospital, London, UK
| | - Riz Ahmed
- Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK.,Department of Clinical Oncology, West Middlesex University Hospital, London, UK
| | - Waheeda Owadally
- Department of Clinical Oncology, The Royal United Hospital, Combe Park, Bath, UK
| | - Barbara Stanley
- Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Deep Shah
- Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - Ondrej Gojis
- Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
| | - Adam Januszewski
- Department of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
| | | | - Rebecca Asher
- Cancer Research UK Liverpool Cancer Trials Unit, Liverpool, UK
| | - Daniel Lythgoe
- Cancer Research UK Liverpool Cancer Trials Unit, Liverpool, UK
| | - Evandro de Azambuja
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Mark Beresford
- Department of Clinical Oncology, The Royal United Hospital, Combe Park, Bath, UK
| | - Sacha J Howell
- University of Manchester, Institute of Cancer Sciences, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
12
|
Park K, Lewanski C, Gadgeel S, Fehrenbacher L, Mazieres J, Rittmeyer A, Han J, Artal-Cortes A, Braiteh F, Gandhi M, Yu W, Matheny C, He P, Sandler A, Ballinger M, Vansteenkiste J. MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.535] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Morgensztern D, Ong T, Dols MC, Aix SP, Postmus P, Lewanski C, Bennouna J, Fischer J, Vidal O, Stewart D, Fasola G, Ardizoni A, Weaver J, Wolfsteiner M, Talbot D, Govindan R. ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer 2017; 83:302-312. [PMID: 28780466 PMCID: PMC5597318 DOI: 10.1016/j.ejca.2017.05.037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 05/19/2017] [Indexed: 01/19/2023]
Abstract
BACKGROUND Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes. METHODS The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m2 on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m2 (GC80) or cisplatin 50 mg/m2 (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles. Primary outcome measure was survival time, aiming to test for a difference between treatment arms and also assess non-inferiority with pre-defined margin selected as hazard ratio (HR) of 1.2. Secondary outcome measures included response rate, adverse events and quality of life (QoL). FINDINGS The trial recruited 1363 patients. Survival time differed significantly across the three treatment arms (p = 0.046) with GC50 worst with median 8.2 months compared to 9.5 for GC80 and 10.0 for GCb6. HRs (adjusted) for GC50 compared to GC80 was 1.13 (95% confidence interval [CI] 0.99-1.29) and for GC50 compared to GCb6 was 1.23 (95% CI: 1.08-1.41). GCb6 was significantly non-inferior to GC80 (HR = 0.93, upper limit of one-sided 95% CI 1.04). Adjusting for QoL did not change the findings. Best objective response rates were 29% (GC80), 20% (GC50) and 27% (GCb6), p < 0.007. There were more dose reductions and treatment delays in the GCb6 arm and more adverse events (60% with at least one grade 3-4 compared to 43% GC80 and 30% GC50). INTERPRETATION In combination with gemcitabine, carboplatin at AUC6 is not inferior to cisplatin at 80 mg/m2 in terms of survival. Carboplatin was associated with more adverse events and not with better quality of life. Cisplatin at the lower dose of 50 mg/m2 has worse survival which is not compensated by better quality of life. CLINICALTRIALS. GOV IDENTIFIER NCT00112710. EUDRACT NUMBER 2004-003868-30. CANCER RESEARCH UK TRIAL IDENTIFIER CRUK/04/009.
Collapse
Affiliation(s)
- David Ferry
- Royal Wolverhampton NHS Trust, Wolverhampton, UK
| | - Lucinda Billingham
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
| | - Hugh Jarrett
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - David Dunlop
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Penella J Woll
- Weston Park Hospital, University of Sheffield, Sheffield, UK
| | | | - Riyaz Shah
- Kent Oncology Centre, Maidstone Hospital, Maidstone, UK
| | | | - James Spicer
- King's College London, Guy's Hospital, London, UK
| | | | | | - Pauline Leonard
- Whittington Health NHS Trust, Whittington Hospital, London, UK
| | | | | | - Conrad Lewanski
- Imperial College Healthcare, Charing Cross Hospital, London, UK
| | - Barbara Crosse
- Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK
| | - Michelle Hill
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - Piers Gaunt
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | | |
Collapse
|
15
|
Artal-Cortes A, Mazieres J, Fehrenbacher L, Rittmeyer A, Spira A, Park K, Lewanski C, Liu S, Ballinger M, Vansteenkiste J. Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Rittmeyer A, Smith D, Vansteenkiste J, Fehrenbacher L, Park K, Mazieres J, Artal-Cortes A, Lewanski C, Braiteh F, Yi J, He P, Zou W, Waterkamp D, Ballinger M, Chen DS, Sandler A, Spira AI. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). Pneumologie 2017. [DOI: 10.1055/s-0037-1598330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - D Smith
- US Oncology Research, Compass Oncology, Vancouver
| | | | | | - K Park
- Division of Hematology/Oncology, Samsung Medical Centre
| | | | - A Artal-Cortes
- Servicio de Oncologia Medica, Hospital Universitario Miguel Servet
| | - C Lewanski
- Department of Oncology, Charing Cross Hospital
| | - F Braiteh
- US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas
| | | | | | | | | | | | | | | | - AI Spira
- US Oncology Research, Virginia Cancer Specialists Research Institute, Fairfax
| |
Collapse
|
17
|
Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J Clin Oncol 2017; 35:402-411. [PMID: 27893326 DOI: 10.1200/jco.2016.68.1841] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor. Chemonaïve patients with NSCLC (stage IIIB and IV) were eligible. Patients with squamous histology were randomly assigned to cisplatin and gemcitabine or paclitaxel and gemcitabine; nonsquamous patients received cisplatin and pemetrexed or paclitaxel and pemetrexed. Primary end point was overall survival (OS). We also evaluated an antibody specific for XPF (clone 3F2). The target hazard ratio (HR) for patients with ERCC1-positive NSCLC was ≤ 0.78. Results Of patients, 648 were recruited (177 squamous, 471 nonsquamous). ERCC1-positive rates were 54.5% and 76.7% in nonsquamous and squamous patients, respectively, and the corresponding XPF-positive rates were 70.5% and 68.5%. Accrual stopped early in 2012 for squamous patients because OS for nonplatinum therapy was inferior to platinum therapy (median OS, 7.6 months [paclitaxel and gemcitabine] v 10.7 months [cisplatin and gemcitabine]; HR, 1.46; P = .02). Accrual for nonsquamous patients halted in 2013. Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). OS HR was 1.09 (95% CI, 0.83 to 1.44) for XPF-positive patients, and 1.39 (95% CI, 0.90 to 2.15) for XPF-negative patients (interaction P = .35). Neither ERCC1 nor XPF were prognostic: among nonsquamous patients, OS HRs for positive versus negative were ERCC1, 1.11 ( P = .32), and XPF, 1.08 ( P = .55). Conclusion Superior outcomes were observed for patients with squamous histology who received platinum therapy compared with nonplatinum chemotherapy; however, selecting chemotherapy by using commercially available ERCC1 or XPF antibodies did not confer any extra survival benefit.
Collapse
Affiliation(s)
- Siow Ming Lee
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Mary Falzon
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Fiona Blackhall
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - James Spicer
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Marianne Nicolson
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Abhro Chaudhuri
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Gary Middleton
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Samreen Ahmed
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Jonathan Hicks
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Barbara Crosse
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Mark Napier
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Julian M Singer
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - David Ferry
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Conrad Lewanski
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Martin Forster
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Sally-Ann Rolls
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Arrigo Capitanio
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Robin Rudd
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Natasha Iles
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Yenting Ngai
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Michael Gandy
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Rachel Lillywhite
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| | - Allan Hackshaw
- Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom
| |
Collapse
|
18
|
Popat S, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Ngai Y, Hackshaw A. P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1713] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y. PD
‐L1 testing for lung cancer in the
UK
: recognizing the challenges for implementation. Histopathology 2016; 69:177-86. [DOI: 10.1111/his.12996] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Ian A Cree
- Department of Pathology University Hospitals Coventry and Warwickshire NHS Trust Coventry UK
| | - Richard Booton
- Respiratory and Allergy Research Group Institute of Inflammation & Repair North West Lung Centre University of Manchester University Hospital of South Manchester NHS Foundation Trust Manchester UK
| | - Paul Cane
- Department of Histopathology Guy's and St Thomas' NHS Foundation Trust London UK
| | - John Gosney
- Department of Pathology Royal Liverpool and Broadgreen University Hospitals NHS Trust Liverpool UK
| | - Merdol Ibrahim
- UK National External Quality Assessment Service for Immunocytochemistry and In Situ Hybridisation London UK
| | - Keith Kerr
- Department of Pathology Aberdeen Royal Infirmary/Aberdeen University Medical School Aberdeen UK
| | - Rohit Lal
- Guy's and St Thomas' NHS Foundation Trust London UK
| | - Conrad Lewanski
- Oncology Department Charing Cross Hospital Imperial College Healthcare NHS Trust London UK
| | - Neal Navani
- Lungs for Living Research Centre UCL Respiratory University College London Hospitals NHS Foundation Trust London UK
| | - Andrew G Nicholson
- Royal Brompton and Harefield Hospitals NHS Foundation Trust and National Heart and Lung Division Imperial College London UK
| | - Marianne Nicolson
- Department of Oncology NHS Grampian Aberdeen Royal Infirmary Aberdeen UK
| | - Yvonne Summers
- The Christie Hospital NHS Foundation Trust Manchester UK
| |
Collapse
|
20
|
Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, Pepperell J, Howell T, Stewart SA, Penz E, Jordan N, Morley AJ, Zahan-Evans N, Smith S, Batchelor TJP, Marchbank A, Bishop L, Ionescu AA, Bayne M, Cooper S, Kerry A, Jenkins P, Toy E, Vigneswaran V, Gildersleve J, Ahmed M, McDonald F, Button M, Lewanski C, Comins C, Dakshinamoorthy M, Lee YCG, Rahman NM, Maskell NA. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol 2016; 17:1094-1104. [PMID: 27345639 PMCID: PMC4961873 DOI: 10.1016/s1470-2045(16)30095-x] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 04/14/2016] [Accepted: 04/15/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND The use of prophylactic radiotherapy to prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical practice varies worldwide. We aimed to compare prophylactic radiotherapy with deferred radiotherapy (given only when a PTM developed) in a suitably powered trial. METHODS We did a multicentre, open-label, phase 3, randomised controlled trial in 22 UK hospitals of patients with histocytologically proven mesothelioma who had undergone large-bore pleural interventions in the 35 days prior to recruitment. Eligible patients were randomised (1:1), using a computer-generated sequence, to receive immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention) or deferred radiotherapy (same dose given within 35 days of PTM diagnosis). Randomisation was minimised by histological subtype, surgical versus non-surgical procedure, and pleural procedure (indwelling pleural catheter vs other). The primary outcome was the incidence of PTM within 7 cm of the site of pleural intervention within 12 months from randomisation, assessed in the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN72767336. FINDINGS Between Dec 23, 2011, and Aug 4, 2014, we randomised 203 patients to receive immediate radiotherapy (n=102) or deferred radiotherapy (n=101). The patients were well matched at baseline. No significant difference was seen in PTM incidence in the immediate and deferred radiotherapy groups (nine [9%] vs 16 [16%]; odds ratio 0·51 [95% CI 0·19-1·32]; p=0·14). The only serious adverse event related to a PTM or radiotherapy was development of a painful PTM within the radiotherapy field that required hospital admission for symptom control in one patient who received immediate radiotherapy. Common adverse events of immediate radiotherapy were skin toxicity (grade 1 in 50 [54%] and grade 2 in four [4%] of 92 patients vs grade 1 in three [60%] and grade 2 in two [40%] of five patients in the deferred radiotherapy group who received radiotherapy for a PTM) and tiredness or lethargy (36 [39%] in the immediate radiotherapy group vs two [40%] in the deferred radiotherapy group) within 3 months of receiving radiotherapy. INTERPRETATION Routine use of prophylactic radiotherapy in all patients with mesothelioma after large-bore thoracic interventions is not justified. FUNDING Research for Patient Benefit Programme from the UK National Institute for Health Research.
Collapse
Affiliation(s)
- Amelia O Clive
- Respiratory Research Unit, North Bristol National Health Service (NHS) Trust, Southmead Hospital, Bristol, UK; Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | | | - Lee Dobson
- South Devon Healthcare NHS Foundation Trust, Torbay, UK
| | - Paula Wilson
- University Hospitals Bristol NHS Trust, Bristol, UK
| | | | - Niki Panakis
- Oxford University Hospitals NHS Trust, Oxford, UK
| | | | | | | | - Erika Penz
- Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
| | - Nikki Jordan
- Respiratory Research Unit, North Bristol National Health Service (NHS) Trust, Southmead Hospital, Bristol, UK
| | - Anna J Morley
- Respiratory Research Unit, North Bristol National Health Service (NHS) Trust, Southmead Hospital, Bristol, UK
| | - Natalie Zahan-Evans
- Respiratory Research Unit, North Bristol National Health Service (NHS) Trust, Southmead Hospital, Bristol, UK
| | - Sarah Smith
- Respiratory Research Unit, North Bristol National Health Service (NHS) Trust, Southmead Hospital, Bristol, UK
| | | | | | | | - Alina A Ionescu
- Royal Gwent Hospital, Aneurin Bevan University Health Board, Newport, UK
| | - Mike Bayne
- Poole Hospital NHS Foundation Trust, Poole, UK; Dorset County Hospital NHS Foundation Trust, Dorchester, UK
| | - Samantha Cooper
- Colchester Hospital University NHS Foundation Trust, Colchester, UK
| | | | - Peter Jenkins
- Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK
| | - Elizabeth Toy
- Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
| | | | | | - Merina Ahmed
- The Royal Marsden NHS Foundation Trust, London, UK
| | | | | | | | | | | | - Y C Gary Lee
- Centre for Respiratory Health, School of Medicine & Pharmacology, University of Western Australia, Perth, WA, Australia
| | - Najib M Rahman
- Oxford University Hospitals NHS Trust, Oxford, UK; Oxford National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, UK
| | - Nick A Maskell
- Respiratory Research Unit, North Bristol National Health Service (NHS) Trust, Southmead Hospital, Bristol, UK; Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
| |
Collapse
|
21
|
Camidge DR, Moran T, Demedts I, Grosch H, Di Mercurio JP, Mileham KF, Molina JR, Juan Vidal O, Bepler G, Goldman JW, Lewanski C, Park K, Wallin J, Wijayawardana SR, Wang XA, Wacheck V, Smit EF. A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.9070] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Keunchil Park
- Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | | | | | | | | | | |
Collapse
|
22
|
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387:1837-46. [PMID: 26970723 DOI: 10.1016/s0140-6736(16)00587-0] [Citation(s) in RCA: 2048] [Impact Index Per Article: 256.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody atezolizumab is clinically active against cancer, including NSCLC, especially cancers expressing PD-L1 on tumour cells, tumour-infiltrating immune cells, or both. We assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumour cells and tumour-infiltrating immune cells and in the intention-to-treat population. METHODS In this open-label, phase 2 randomised controlled trial, patients with NSCLC who progressed on post-platinum chemotherapy were recruited in 61 academic medical centres and community oncology practices across 13 countries in Europe and North America. Key inclusion criteria were Eastern Cooperative Oncology Group performance status 0 or 1, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), and adequate haematological and end-organ function. Patients were stratified by PD-L1 tumour-infiltrating immune cell status, histology, and previous lines of therapy, and randomly assigned (1:1) by permuted block randomisation (with a block size of four) using an interactive voice or web system to receive intravenous atezolizumab 1200 mg or docetaxel 75 mg/m(2) once every 3 weeks. Baseline PD-L1 expression was scored by immunohistochemistry in tumour cells (as percentage of PD-L1-expressing tumour cells TC3≥50%, TC2≥5% and <50%, TC1≥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3≥10%, IC2≥5% and <10%, IC1≥1% and <5%, and IC0<1%). The primary endpoint was overall survival in the intention-to-treat population and PD-L1 subgroups at 173 deaths. Biomarkers were assessed in an exploratory analysis. We assessed safety in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01903993. FINDINGS Patients were enrolled between Aug 5, 2013, and March 31, 2014. 144 patients were randomly allocated to the atezolizumab group, and 143 to the docetaxel group. 142 patients received at least one dose of atezolizumab and 135 received docetaxel. Overall survival in the intention-to-treat population was 12·6 months (95% CI 9·7-16·4) for atezolizumab versus 9·7 months (8·6-12·0) for docetaxel (hazard ratio [HR] 0·73 [95% CI 0·53-0·99]; p=0·04). Increasing improvement in overall survival was associated with increasing PD-L1 expression (TC3 or IC3 HR 0·49 [0·22-1·07; p=0·068], TC2/3 or IC2/3 HR 0·54 [0·33-0·89; p=0·014], TC1/2/3 or IC1/2/3 HR 0·59 [0·40-0·85; p=0·005], TC0 and IC0 HR 1·04 [0·62-1·75; p=0·871]). In our exploratory analysis, patients with pre-existing immunity, defined by high T-effector-interferon-γ-associated gene expression, had improved overall survival with atezolizumab. 11 (8%) patients in the atezolizumab group discontinued because of adverse events versus 30 (22%) patients in the docetaxel group. 16 (11%) patients in the atezolizumab group versus 52 (39%) patients in the docetaxel group had treatment-related grade 3-4 adverse events, and one (<1%) patient in the atezolizumab group versus three (2%) patients in the docetaxel group died from a treatment-related adverse event. INTERPRETATION Atezolizumab significantly improved survival compared with docetaxel in patients with previously treated NSCLC. Improvement correlated with PD-L1 immunohistochemistry expression on tumour cells and tumour-infiltrating immune cells, suggesting that PD-L1 expression is predictive for atezolizumab benefit. Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy. FUNDING F Hoffmann-La Roche/Genentech Inc.
Collapse
Affiliation(s)
| | - Alexander Spira
- US Oncology Research, The Woodlands, TX, USA; Virginia Cancer Specialists Research Institute, Fairfax, VA, USA
| | | | | | | | - Julien Mazieres
- Toulouse University Hospital, Paul Sabatier University, Toulouse, France
| | - Keunchil Park
- Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - David Smith
- US Oncology Research, The Woodlands, TX, USA; Compass Oncology, Vancouver, WA, USA
| | - Angel Artal-Cortes
- Servicio de Oncologia Medica, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | - Fadi Braiteh
- US Oncology Research, The Woodlands, TX, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA
| | | | - Pei He
- Genentech, South San Francisco, CA, USA
| | - Wei Zou
- Genentech, South San Francisco, CA, USA
| | | | - Jing Yi
- Genentech, South San Francisco, CA, USA
| | | | | |
Collapse
|
23
|
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:953-62. [PMID: 26811519 DOI: 10.1200/jco.2015.64.8824] [Citation(s) in RCA: 297] [Impact Index Per Article: 37.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
PURPOSE The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposide-cisplatin and TRT followed by nonpemetrexed doublet consolidation therapy. PATIENTS AND METHODS Patients with stage IIIA/B unresectable nonsquamous non-small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m(2) and cisplatin 50 mg/m(2) intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B). The primary objective was OS. The study was designed as a superiority trial with 80% power to detect an OS hazard ratio of 0.74 with a type 1 error of .05. RESULTS Enrollment was stopped early because of futility. Five hundred ninety-eight patients were randomly assigned (301 to arm A, 297 to arm B) and 555 patients (283 in arm A, 272 in arm B) were treated. Arm A was not superior to arm B in terms of OS (hazard ratio, 0.98; 95% CI, 0.79 to 1.20; median, 26.8 v 25.0 months; P = .831). Arm A had a significantly lower incidence of any drug-related grade 3 to 4 adverse events (64.0% v 76.8%; P = .001), including neutropenia (24.4% v 44.5%; P < .001), during the overall treatment period. CONCLUSION Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexed was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.
Collapse
Affiliation(s)
- Suresh Senan
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France.
| | - Anthony Brade
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Lu-Hua Wang
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Johan Vansteenkiste
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Shaker Dakhil
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Bonne Biesma
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Maite Martinez Aguillo
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Joachim Aerts
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Ramaswamy Govindan
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Belén Rubio-Viqueira
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Conrad Lewanski
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - David Gandara
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Hak Choy
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Tony Mok
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Anwar Hossain
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Neill Iscoe
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Joseph Treat
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Andrew Koustenis
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Bélen San Antonio
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Nadia Chouaki
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| | - Everett Vokes
- Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France
| |
Collapse
|
24
|
Goyal N, Ingle M, Bhuva N, Power D, Lewanski C. 122 To determine ideal gross tumour volumes and PTV expansion using four-dimensional computed tomography for the treatment of lung cancer. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30139-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Mornex F, Senan S, Hennequin C, Lartigau E, Brade A, Wang L, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, Chouaki N, Vokes E. PROCLAIM : résultats finaux de survie globale de l’essai de phase III : pemetrexed cisplatine ou étoposide cisplatine, plus radiothérapie thoracique suivie d’une chimiothérapie de consolidation dans le CBNPC non épidermoïde localement avancé. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Vansteenkiste J, Fehrenbacher L, Spira A, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Yi J, He P, Kowanetz M, Waterkamp D, Ballinger M, Chen D, Sandler A, Rittmeyer A. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30072-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Palmieri C, Macpherson IRJ, Yan K, Ades Moraes F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, De Azambuja E, Beresford M, Howell SJ. Abstract P4-15-05: Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p4-15-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Neoadjuvant chemotherapy delivered with trastuzumab (NCT) has been shown to increase the rates of pathological complete response (pCR) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting has been associated with improved event free survival (EFS). However, no study has yet investigated the effect on outcomes of NCT compared to NC followed by adjuvant trastuzumab initiated postoperatively (NCAT). This study sought to investigate the impact on breast cancer outcomes of concomitant (NCT) versus sequential (NCAT) treatment in HER2 positive early breast cancer.
Methods:
Women with HER2 positive invasive breast cancers treated with neoadjuvant chemotherapy between 2006-2010 were identified at each of 7 European institutions and the case notes reviewed. Preoperative clinical, radiological and pathological details, treatment details and pathology results following breast surgery were reviewed. To be defined as NCT at least one dose of trastuzumab needed to be given preoperatively. pCR was defined as absence of invasive disease in breast and lymph nodes. Multivariable Cox regression and logistic regression were used to Survival outcomes for event-free survival (EFS) were calculated by log rank analysis model the influence of a number of factors on event-free survival (EFS) and pCR respectively.
Results:
236 patients were identified; 138 (58%) received NCAT & 98 (42%) received NCT. The median follow up for the whole group was 53.7 months (IQR 41.7-68.8), 61.5 months (IQR 50.3-78.5) for NCAT group and 44.8 months (range 37-53.9) for NCT group. The 5-year EFS for NCAT vs NCT was 59.3% (95% CI: 49.8-67.6) and 69.6% (95% CI: 51.5-82.0) respectively. The unadjusted hazard ratio (HR) for EFS with NCT compared with the NCAT was 0.63 (95% CI 0.37–1.08; p=0.091). NCT significantly increased the odds of having pCR relative to NC (OR: 4.39 (2.18-8.86); p<0.001), and pCR was associated with a significantly improved EFS, with an unadjusted HR of 0.23 (95% CI 0.08–0.64; p=0.002). Multivariable analysis revealed that treatment group, tumour size and ER status were significantly associated with EFS. NCT was associated with a reduced risk of relapse relative to NCAT (HR 0.48, 95% CI 0.26-0.89). In ER negative tumours NCT was significantly associated with a reduced risk of an event relative to NCAT (HR:0.25; 95% CI, 0.10-0.62), this was not observed for ER positive tumours (HR: 1.07; 95% CI, 0.46-2.52).
Conclusion
Concomitant as compared to sequential trastuzumab is associated with improved outcomes in the neoadjvuant setting for women with ER negative tumours. These data further support the need for the early introduction of targeted combination therapy in women with ER negative/HER2 positive BC.
Citation Format: Carlo Palmieri, Iain RJ Macpherson, Kelvin Yan, Felipe Ades Moraes, Pippa Riddle, Riz Ahmed, Waheeda Owadally, Barabara Stanley, Deep Shah, Ondrej Gojis, Adam Januszewski, Conrad Lewanski, Rebecca Asher, Daniel Lythgoe, Evandro De Azambuja, Mark Beresford, Sacha J Howell. Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-15-05.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Deep Shah
- 3Imperial College Healthcare NHS Trust
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Lee S, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer J, Ferry D, Lewanski C, Rolls S, Iles N, Ngai Y, Lillywhite R, Falzon M, Rudd R, Hackshaw A. Et: a Randomized, Multicenter, Phase III Trial of Platinum Versus Nonplatinum Chemotherapy, After Ercc1 Stratification, in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Göksel T, Park K, Kowalyszyn R, Pikiel J, Lewanski C, Thomas M, Dakhil S, Kim J, Karaseva N, Yurasov S, Zimmermann A, Carter GC, Reck M, Cappuzzo F, Perol M. Quality of Life (Qol) Results from the Phase 3 Revel Study of Ramucirumab + Docetaxel (Ram + Dtx) Versus Placebo + Docetaxel (Pl + Dtx) in Advanced/Metastatic Nsclc Patients (Pts) with Progression After Platinum Based Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Lewanski C, Hennig I, Tahir S, Benepal T, Skaria S, Kabuubi P, Power D, Summerhayes M, Trani L. 19 EGFR mutation rate in TRANSCRIPT: A study to assess the incidence of EGFR mutations in UK NSCLC patients with newly diagnosed locally advanced or metastatic disease. A single arm, open label study. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70020-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012; 13:1161-70. [PMID: 23078958 PMCID: PMC3488187 DOI: 10.1016/s1470-2045(12)70412-6] [Citation(s) in RCA: 133] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients. Methods TOPICAL was a double-blind, randomised, placebo-controlled, phase 3 trial, done at 78 centres in the UK. Eligibility criteria were newly diagnosed, pathologically confirmed NSCLC; stage IIIb or IV; chemotherapy naive; no symptomatic brain metastases; deemed unsuitable for chemotherapy because of poor (≥2) Eastern Cooperative Oncology Group performance status or presence of several comorbidities, or both; and estimated life expectancy of at least 8 weeks. Patients were randomly assigned (by phone call, in a 1:1 ratio, stratified by disease stage, performance status, smoking history, and centre, block size 10) to receive oral placebo or erlotinib (150 mg per day) until disease progression or unacceptable toxicity. Investigators, clinicians, and patients were masked to assignment. The primary endpoint was overall survival. Analyses were by intention to treat, and prespecified subgroup analyses included development of a rash due to erlotinib within 28 days of starting treatment. This study is registered, number ISRCTN 77383050. Findings Between April 14, 2005, and April 1, 2009, we randomly assigned 350 patients to receive erlotinib and 320 to receive placebo. We followed up patients until March 31, 2011. 657 patients died; median overall survival did not differ between groups (erlotinib, 3·7 months, 95% CI 3·2–4·2, vs placebo, 3·6 months, 3·2–3·9; unadjusted hazard ratio [HR] 0·94, 95% CI 0·81–1·10, p=0·46). 59% (178 of 302) of patients assigned erlotinib and who were assessable at 1 month developed first-cycle rash, which was the only independent factor associated with overall survival. Patients with first-cycle rash had better overall survival (HR 0·76, 95% CI 0·63–0·92, p=0·0058), compared with placebo. Compared with placebo, overall survival seemed to be worse in the group that did not develop first-cycle rash (1·30, 1·05–1·61, p=0·017). Grade 3 or 4 diarrhoea was more common with erlotinib than placebo (8% [28 of 334] vs 1% [four of 313], p=0·0001), as was high-grade rash (23% [79 of 334] vs 2% [five of 313], p<0·0001); other adverse events were much the same between groups. Interpretation Patients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib. Patients who develop a first-cycle rash should continue to receive erlotinib, whereas those who do not have a rash after 28 days should discontinue erlotinib, because of the possibility of decreased survival. Funding Cancer Research UK, Roche.
Collapse
Affiliation(s)
- Siow Ming Lee
- University College London Cancer Institute and University College London Hospitals, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lee S, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Ngai Y, Rudd R, Hackshaw A, Boshoff C. Topical: Randomized Phase III Trial of Erlotinib Compared with Placebo in Patients with Advanced Non–Small Cell Lung Cancer (NSCLC) Unsuitable for First-Line Chemotherapy: Updated Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33878-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
33
|
Ferry D, Billingham LJ, Jarrett HW, Dunlop D, Thompson J, Kumar M, Skailes G, Nicolson M, Shah R, Leonard P, Chetiyawardana A, Wells P, Lewanski C, Woll P, Crosse B, Hill M, Pirrie S, O'Byrne KJ. S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054b.85] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Billingham LJ, Gaunt P, Jarrett HW, Dunlop D, Thompson J, O'Byrne KJ, Kumar M, Skailes G, Nicolson M, Shah R, Leonard P, Chetiyawardana A, Wells P, Lewanski C, Woll P, Crosse B, Hill M, Ferry D. S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients. Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054b.86] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
35
|
Dunlop D, Ferry D, Jarrett HW, Billingham LJ, Thompson J, Kumar M, Skailes G, Nicolson M, Shah R, Leonard P, Chetiyawardana A, Wells P, Lewanski C, Woll P, Crosse B, O'Byrne KJ. S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes. Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054b.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Keane MG, Haboubi J, Lewanski C. A rare complication of finger sepsis secondary to blood glucose monitoring. Case Reports 2009; 2009:bcr06.2009.2010. [DOI: 10.1136/bcr.06.2009.2010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
37
|
Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 2001; 37:2015-22. [PMID: 11597379 DOI: 10.1016/s0959-8049(01)00216-7] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A phase II trial of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy was conducted in 20 patients with treatment-naïve squamous cell cancer of the head and neck (SCCHN). 10 patients received two cycles of Caelyx (40 mg/m(2)) every 3 weeks before starting radical radiotherapy (RT). Subsequently, consecutive groups of 3 patients received a third escalating dose of Caelyx (10, 15 and 20 mg/m(2)) 3 days before RT. 9 of 18 (50%, 95% confidence intervals (CI): 26-74%) evaluable patients responded to Caelyx, with 11 responses in 26 (42%, 95% CI: 24-62%) evaluable sites (three complete responses (12%), eight partial responses (31%)). There was no grade 3/4 haematological, mucosal or cardiac toxicity. Nausea and vomiting were minimal. There were no drug-related RT delays. Local RT-induced toxicity was not increased. Caelyx has significant activity against SCCHN and warrants further investigation in this disease. In view of its tumour targeting properties and activity at moderate doses, it may be useful in concomitant chemoradiotherapy strategies for SCCHN.
Collapse
Affiliation(s)
- K J Harrington
- ICRF Laboratory of Molecular Therapy, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, 150 Du Cane Road, W12 0HS, London, UK.
| | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
The risk of carcinogenesis from radiation exposure is well known. It has been questioned for some time therefore, whether it is wise to treat benign disease with radiotherapy. We report a case of a patient who developed bilateral breast carcinomas almost 30 years after treatment of chest wall keloids with radiotherapy. There are only anecdotal reports in the literature of malignancies following treatment of keloids with radiotherapy. We review these reports and discuss the safety of this approach to the management of keloid scars.
Collapse
Affiliation(s)
- N Botwood
- Department of Radiology, Charing Cross Hospital, London, UK
| | | | | |
Collapse
|
39
|
Gullick W, Lewanski C. Coronary angioplasty: an end to early closing? Gene Ther 1999; 6:954-5. [PMID: 10455396 DOI: 10.1038/sj.gt.3300960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- W Gullick
- Receptor Biology Laboratory, Imperial Cancer Research Fund, Molecular Oncology Unit, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | | |
Collapse
|
40
|
Harrington KJ, Pandha HS, Hollyer JS, Kelly SA, Bateman AR, Lewanski C, Morris P, Jackson JE. Risk factors for pneumothorax during percutaneous Hickman line insertion in patients with solid and haematological tumours. Clin Oncol (R Coll Radiol) 1995; 7:373-6. [PMID: 8590699 DOI: 10.1016/s0936-6555(05)80008-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The purpose of this study was to identify risk factors for pneumothorax during percutaneous subclavian Hickman line insertion in patients with haematological (HT) or solid tumours (ST). One hundred and twelve patients (55 HT, 57 ST) had 132 subclavian Hickman lines inserted under fluoroscopic control. Lines were inserted on the left on 116 occasions and the right in 16. Thirty-five single, 29 double and 68 triple lumen catheters were inserted. Variables included in the analysis were age, sex, side of insertion, catheter gauge and nutritional status as indicated by the body mass index (BMI kg/m2). Both univariate and logistic regression analyses were performed. There were ten pneumothoraces, all occurring in patients with STs. Univariate analysis revealed that patients with STs were older (median age 59 versus 36 years; P = 0.0001) and more cachectic (median BMI 21.9 versus 24.2 kg/m2; P = 0.03) than those with HTs, and the patients experiencing pneumothorax were older (median age 57 versus 44 years; P < 0.01) and more cachectic (median BMI 19.6 versus 24.0 kg/m2; P = 0.004) than those undergoing uncomplicated procedures. For patients with a BMI < 19 kg/m2 versus those with a BMI > 19 kg/m2, the pneumothorax rate was 5/8 versus 5/124 (P < 0.00001). Logistic regression analysis confirmed the significantly older age of the patients with STs (P < 0.001) and of those experiencing pneumothorax (P = 0.02). This analysis also confirmed the lower BMI of patients experiencing pneumothorax (P = 0.002). The patients' sex, the side of line insertion and the catheter gauge were not associated with pneumothorax on either the univariate or logistic regression analyses. From these data we conclude that pneumothorax complicating a subclavian Hickman line is significantly more likely in elderly patients with a low BMI. Such patients are more likely to have STs than HTs. In patients with a BMI < 19 kg/m2, the subclavian route should be used with caution.
Collapse
Affiliation(s)
- K J Harrington
- Department of Clinical Oncology, Hammersmith Hospital, London, UK
| | | | | | | | | | | | | | | |
Collapse
|